AstraZeneca | Rx Times Pharmacy Magazine

Pfizer cancels bid to purchase AstraZeneca

Posted By: Staff Writeron: May 26, 2014In: Pharmaceutical

After many recent attempts to combine two companies into one, Pfizer decides to call it quits when it comes to purchasing AstraZenaca. Following AstraZenaca’s board’s rejection of the roughl... Read more

Over-The-Counter Nexium

Posted By: Rx Timeson: August 13, 2012In: Pharmaceutical

Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescripti... Read more

Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes

Posted By: Rx Timeson: November 16, 2011In: Pharmaceutical

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a pre-specified meta-analysis of cardiovascular (CV) safety data from 14 Phase 2b/3 trials i... Read more

U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months

Posted By: Rx Timeson: October 26, 2011In: Pharmaceutical

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for dapagliflozin for the t... Read more

FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin

Posted By: Rx Timeson: July 21, 2011In: Pharmaceutical

PRINCETON, N.J. & WILMINGTON, Del. – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today reported the outcome of the U.S. Food and Drug Administration... Read more

Phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis

Posted By: Rx Timeson: October 27, 2010In: Pharmaceutical

AstraZeneca announced that it has commenced dosing patients in a global Phase IIb study to compare the efficacy and safety of AZD9773 (CytoFab) with placebo in adult patients with severe sep... Read more

Seroquel XR Recommended For Approval In EU as an Add-On Treatment Of Major Depressive Disorder

Posted By: Rx Timeson: April 23, 2010In: Pharmaceutical

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA) concluded that the benefit-risk profile of once-daily SEROQ... Read more

Jury Rules In Favor Of AstraZeneca

Posted By: Rick Jacksonon: March 18, 2010In: Pharmaceutical

A jury in a New Jersey state court ruled in favor of AstraZeneca by rejecting a Louisiana plaintiff’s claims that Seroquel caused alleged injuries. AstraZeneca, a global biopharmaceutical bu... Read more

U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza™ (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults

Posted By: Rx Timeson: March 17, 2010In:

PRINCETON, N.J. & WILMINGTON, Del. – Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accep... Read more

Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)

Posted By: Rx Timeson: March 15, 2010In: Pharmaceutical

PRINCETON, N.J. & WILMINGTON, Del.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the “Saxagliptin A... Read more

Newsletter

Featured Jobs

Newsletter

Subscribe to our email newsletter.

Popular